3 documents found, page 1 of 1
New pharmacological agents and novel cardiovascular pharmacotherapy strategies ...
Tamargo, Juan; Agewall, Stefan; Ambrosio, Giuseppe; Borghi, Claudio; Cerbai, Elisabetta; Dan, Gheorghe A; Drexel, Heinz; Ferdinandy, PéterDespite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVDs) remain limited, thus reflecting the need for more effective and safer pharmacological strategies. In this review, we summarize the most relevant studies in cardiovascular pharmacotherapy in 2024, including the approval of first-in-class drugs for the treatme...
European Journal of Heart Failure consensus statement. Heart failure pharmacoth...
Luedde, Mark; Agewall, Stefan; Ambrosio, Giuseppe; Bayes‐Genis, Antoni; Borghi, Claudio; Cerbai, Elisabetta; Dan, Gheorghe A.; Drexel, HeinzHeart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non-adherence and side effects. While rhythm control strategies in AF have gained attention...
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation dev...
Hindricks, Gerhard; Potpara, Tatjana; Dagres, Nikolaos; Arbelo, Elena; Bax, Jeroen J.; Blomström-Lundqvist, Carina; Boriani, Giuseppe; Castella, ManuelAtrial fibrillation (AF) poses significant burden to patients, physicians, and healthcare systems globally. Substantial research efforts and resources are being directed towards gaining detailed information about the mechanisms underlying AF, its natural course and effective treatments (see also the ESC Textbook of Cardiovascular Medicine: CardioMed) and new evidence is continuously generated and published. The...